海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002653 海思科

交易中 04-15 10:09:00

{"stockData":{"symbol":"002653","market":"SZ","secType":"STK","nameCN":"海思科","latestPrice":57.98,"timestamp":1776218940000,"preClose":58.48,"halted":0,"volume":3441901,"delay":0,"changeRate":-0.0085,"floatShares":537000000,"shares":1120000000,"eps":0.1105,"marketStatus":"交易中","change":-0.5,"latestTime":"04-15 10:09:00","open":59.37,"high":59.88,"low":56.86,"amount":200000000,"amplitude":0.0516,"askPrice":57.97,"askSize":50,"bidPrice":57.8,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.1105,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1776223800000},"marketStatusCode":2,"adr":0,"adjPreClose":58.48,"symbolType":"stock","openAndCloseTimeList":[[1776216600000,1776223800000],[1776229200000,1776236400000]],"highLimit":64.33,"lowLimit":52.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1119917970,"isCdr":false,"pbRate":15.27,"roa":"--","peRate":524.705882,"roe":"6.11%","epsLYR":0.23,"committee":-0.522013,"marketValue":64933000000,"turnoverRate":0.0064,"status":1,"floatMarketCap":31123000000},"requestUrl":"/m/hq/s/002653","defaultTab":"news","newsList":[{"id":"2627469157","title":"海思科（002653）2025年年报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2627469157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627469157?lang=zh_cn&edition=full","pubTime":"2026-04-14 06:02","pubTimestamp":1776117764,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海思科发布2025年年报。根据财报显示，海思科增收不增利。截至本报告期末，公司营业总收入43.88亿元，同比上升17.91%，归母净利润2.6亿元，同比下降34.36%。该数据低于大多数分析师的预期，此前分析师普遍预期2025年净利润为盈利5.4亿元左右。本次财报公布的各项数据指标表现一般。从历史年报数据统计来看，公司近10年来中位数ROIC为10.42%，中位投资回报一般，其中最惨年份2025年的ROIC为4.3%，投资回报一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400003257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","BK0188","BK0077","BK0028","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627943358","title":"4月13日海思科涨8.04%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627943358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627943358?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:16","pubTimestamp":1776068165,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日海思科涨8.04%创60日新高，收盘报60.63元，换手率2.33%，成交量12.52万手，成交额7.33亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共58家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.8587，较上一交易日上涨0.76%，近一年上涨22.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300020098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","002653","BK0033","BK0188","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626174784","title":"海思科(002653)3月31日股东户数1.07万户，较上期增加0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626174784","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626174784?lang=zh_cn&edition=full","pubTime":"2026-04-12 17:02","pubTimestamp":1775984522,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海思科披露，截至2026年3月31日公司股东户数为1.07万户，较12月31日增加89.0户，增幅为0.84%。在化学制药行业个股中，海思科股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年3月31日，海思科区间涨幅为5.77%，在此期间股东户数增加89.0户，增幅为0.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200007416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","002653","BK0033","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626745221","title":"海思科最新公告：2025年净利润同比下降34.36%拟10派2.67元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626745221","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626745221?lang=zh_cn&edition=full","pubTime":"2026-04-12 16:20","pubTimestamp":1775982034,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)发布2025年年度报告，实现营业收入43.88亿元，同比增长17.91%；归属于上市公司股东的净利润为2.60亿元，同比下降34.36%。公司拟以11.2亿股为基数，向全体股东每10股派发现金红利2.67元(含税)，送红股0股，不以公积金转增股本。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200004852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165970887","title":"海思科将获3000万美元首付款，潜在里程碑付款最高可达7.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165970887","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165970887?lang=zh_cn&edition=full","pubTime":"2026-04-12 16:12","pubTimestamp":1775981533,"startTime":"0","endTime":"0","summary":"海思科医药集团宣布，公司将获得3000万美元的首付款，并有资格获得最高达7.15亿美元的潜在里程碑付款。此次交易涉及与艾伯维公司的合作协议，标志着海思科在创新药研发领域的重大进展。根据协议条款，海思科将负责特定研发项目的推进，而艾伯维公司将基于项目进展支付相应款项。这一合作不仅为海思科带来即时的资金支持，还为其长期发展提供了重要的财务保障。业界认为，此类高额里程碑付款安排，凸显了海思科研发能力的国际认可度，有望进一步提升其在全球医药市场的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0942090050.USD","LU0882574055.USD","LU0912757837.SGD","IE0004445239.USD","IE000MB6IJN5.SGD","LU0289739343.SGD","LU1244550577.SGD","IE000WAW04H5.SGD","LU1162221912.USD","LU1023059063.AUD","LU0203347892.USD","IE00B2B36J28.USD","IE00B42XCP33.USD","LU0234570918.USD","BK4139","LU0417517546.SGD","LU2237443549.SGD","LU1057294990.SGD","LU0985320562.USD","LU1267930490.SGD","LU1989771016.USD","SG9999015952.SGD","SG9999001440.SGD","LU2112291526.USD","LU0861579265.USD","LU1983299246.USD","LU1718418525.SGD","LU0795875169.SGD","LU0069063385.USD","LU1732799900.SGD","LU1430594728.SGD","IE00BLSP4452.SGD","LU2129689514.USD","LU2089984988.USD","LU0965508806.USD","LU2133065610.SGD","LU0058720904.USD","LU2129689605.HKD","BK0239","LU1074936037.SGD","LU1291159041.SGD","LU0158827948.USD","LU0432979614.USD","IE00BVYPNV92.GBP","LU0823416689.USD","IE00BGHQF631.EUR","BK4559","LU1551013342.USD","SG9999015945.SGD","ABBV","LU2237443622.USD","LU1929549753.HKD","LU0289739699.SGD","LU2468319806.SGD","LU2129689431.USD","BK4581","LU1093756325.SGD","BK4533","SG9999011175.SGD","LU0795875086.SGD","IE00BJT1NW94.SGD","LU1496350171.SGD","BK4534","LU2023251221.USD","LU0949170772.SGD","LU2237443895.HKD","LU0868494617.USD","LU1585245621.USD","BK0028","LU1003077747.HKD","IE00BDGV0183.EUR","LU2237443382.USD","002653","IE00BLSP4239.USD","LU0310800379.SGD","LU0289961442.SGD","LU0320765646.SGD","SG9999015978.USD","LU0114720955.EUR","BK0077","IE000F7OJYX1.SGD","LU1037948541.HKD","LU1989772840.SGD","LU1093756168.USD","LU1839511570.USD","IE00B3PB1722.GBP","LU0256863811.USD","IE00BJJMRZ35.SGD","BK4566","LU2237443465.HKD","LU0029864427.USD","LU0820561909.HKD","LU1267930573.SGD","IE0002141913.USD","LU0256863902.USD","LU0868494708.USD","IE0000B7K699.USD","LU0708994859.HKD","LU1244550221.USD","LU0198837287.USD","LU0965509283.SGD","LU0211328371.USD","LU2347655156.SGD","LU0553294199.USD","LU1934455194.USD","LU0170899867.USD","IE00BVYPNW00.USD","IE00BBT3K403.USD","IE00BFTCPJ56.SGD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1037948897.HKD","LU2237443978.SGD","IE0002270589.USD","LU0098860793.USD","LU1934455863.HKD","BK0188","IE00BN8TJ469.HKD","LU1551013425.SGD","LU1244550494.USD","LU0456855351.SGD","LU0310799852.SGD","BK4550","LU0203345920.USD","IE000SO60NU8.SGD","IE00BSNM7G36.USD","LU0965509010.AUD","LU0965509101.SGD","LU2089283258.USD","LU0661504455.SGD","SG9999015986.USD","LU0124676726.USD","LU0057025933.USD","LU0738911758.USD","LU0689472784.USD","IE00B4R5TH58.HKD","LU0128525929.USD","BK0033","LU1989772923.USD","LU2089284900.SGD","LU0511384066.AUD","LU0211327993.USD","IE0009355771.USD","LU1934455277.USD","LU1732800096.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0545039389.USD","BK4585","LU0122379950.USD","IE000BZT7R73.USD","LU0689626769.HKD","LU1496350502.SGD","LU0472753341.HKD","LU0820561818.USD","LU0234572021.USD","LU2087621335.USD","LU0943347566.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626717731","title":"海思科最新公告：与AbbVie签署Nav1.8抑制剂授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626717731","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626717731?lang=zh_cn&edition=full","pubTime":"2026-04-12 15:49","pubTimestamp":1775980161,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称，公司与美国AbbVie签订独占许可协议，授予AbbVie在除中国大陆、香港特别行政区及澳门特别行政区以外的全球范围内开发、生产和商业化Nav1.8项目的独家权利。作为对外许可交易对价一部分，公司将从AbbVie获得Nav1.8项目授权许可费（3,000万美元的首付款及最高7.15亿美元的额外里程碑付款）。此外，AbbVie还将会支持授权品种Nav1.8抑制剂在合作项下开发至临床概念验证的一定的研发成本。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200002783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0033","BK0028","002653","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626171216","title":"海思科最新公告：一季度净利同比预增923%-1095%创新药销售保持良好增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2626171216","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626171216?lang=zh_cn&edition=full","pubTime":"2026-04-12 15:40","pubTimestamp":1775979644,"startTime":"0","endTime":"0","summary":"海思科公告称，预计2026年第一季度归属于上市公司股东的净利润为4.77亿元-5.57亿元，比上年同期增长923.34%-1094.97%。公司积极拓展市场，创新药销售持续保持良好增长。因此，在研发费用保持较高增长的情况下，公司归属于上市公司股东的净利润及扣除非经常性损益后的净利润仍实现了较高的增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200002766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002653","BK1161","BK0239","159992","BK1574","BK0033","06978","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625091401","title":"海思科(002653.SZ)：创新药HSK46256片IND申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2625091401","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625091401?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:22","pubTimestamp":1775640177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科 发布公告，公司子公司沈阳海思科制药有限公司于近日收到国家药品监督管理局下发的《受理通知书》，HSK46256是公司自主研发的一个全新的具有独立知识产权的治疗晚期实体瘤的药物。此外，HSK46256具有较好的入脑性质，在颅内瘤药效模型中，可以有效抑制颅内肿瘤增殖，并延长动物生存期，是一款极具开发潜力的小分子药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","159992","06978","BK0239","BK1574","BK0033","IND","BK1161","BK0077","002653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932935","title":"海思科(002653.SZ)：创新药HSK39004吸入粉雾剂纳入突破性治疗药物程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932935","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625932935?lang=zh_cn&edition=full","pubTime":"2026-04-07 16:45","pubTimestamp":1775551552,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)发布公告，公司于2026年4月7日获悉，HSK39004吸入粉雾剂正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》，将极大的推动该领域新药的研发历程，为慢性阻塞性肺病(COPD)患者的治疗带来新的希望。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0033","002653","BK1574","BK0188","BK0239","BK0028","159992","06978","BK1161","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625678475","title":"4月6日海思科发布公告，股东减持697.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625678475","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625678475?lang=zh_cn&edition=full","pubTime":"2026-04-06 17:00","pubTimestamp":1775466057,"startTime":"0","endTime":"0","summary":"证券之星消息，4月6日海思科发布公告《海思科:关于部分5%以上股东之一致行动人股份减持计划实施完成的公告》，其股东郝聪梅、杨飞于2026年3月10日至2026年4月3日间合计减持697.28万股，占公司目前总股本的0.6226%，变动期间该股股价上涨20.96%，截止4月3日收盘报55.34元。股东增减持详情见下表：根据海思科2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600002017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0077","002653","BK0033","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620223453","title":"3月19日海思科发布公告，股东减持216.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620223453","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620223453?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:01","pubTimestamp":1773925261,"startTime":"0","endTime":"0","summary":"证券之星消息，3月19日海思科发布公告《海思科:关于部分5%以上股东之一致行动人减持股份触及1%整数倍的公告》，其股东杨飞于2026年3月17日至2026年3月19日间合计减持216.94万股，占公司目前总股本的0.1937%，变动期间该股股价上涨5.65%，截止3月19日收盘报51.63元。股东增减持详情见下表：根据海思科2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900037357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002653","BK0239","BK0033","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619453804","title":"海思科(002653.SZ)：HSK46575片新增适应症获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453804","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453804?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:27","pubTimestamp":1773649625,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)公告，公司子公司辽宁海思科制药有限公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，本次获得试验批准的药品为HSK46575片，申请的适应症为联合奥拉帕利或联合多西他赛和泼尼松片用于前列腺癌的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海思科(002653.SZ)：HSK46575片新增适应症获药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0033","002653","BK0077","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619453562","title":"3月16日海思科涨5.46%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619453562?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:26","pubTimestamp":1773649614,"startTime":"0","endTime":"0","summary":"证券之星消息，3月16日海思科涨5.46%，收盘报48.87元，换手率0.8%，成交量3.88万手，成交额1.88亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共57家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为138.43亿元，最新净值1.7126，较上一交易日下跌0.2%，近一年上涨9.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600021696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0028","BK0188","BK0239","BK0077","002653","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619943108","title":"海思科最新公告：获得创新药HSK55879片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619943108","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619943108?lang=zh_cn&edition=full","pubTime":"2026-03-15 16:00","pubTimestamp":1773561644,"startTime":"0","endTime":"0","summary":"海思科(002653.SZ)公告称，子公司上海海思盛诺医药科技有限公司近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意HSK55879片开展两个适应症的临床试验。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500004007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002653","06978","BK0239","BK0028","BK1161","159992","BK0033","BK1574","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618189126","title":"海思科(002653.SZ)获得创新药HSK44459乳膏两项适应症IND申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2618189126","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618189126?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:01","pubTimestamp":1773302467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《受理通知书》，涉及药品：“HSK44459乳膏”。HSK44459乳膏是公司自主研发的一个全新的具有独立知识产权的治疗银屑病和特应性皮炎的药物。临床前研究结果表明，本品靶点明确、疗效确切、安全性好，是一款极具开发潜力的小分子药物，临床应用的效益/风险比高，具有广阔的临床应用前景，有望成为银屑病和特应性皮炎的有效治疗药物，解决目前临床用药匮乏的难题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0028","BK1161","BK1574","BK0077","06978","BK0033","159992","IND","002653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640292","title":"3月9日海思科发布公告，股东减持85.78万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618640292?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:01","pubTimestamp":1773054080,"startTime":"0","endTime":"0","summary":"证券之星消息，3月9日海思科发布公告《海思科:关于部分5%以上股东之一致行动人减持股份触及1%整数倍的公告》，其股东郝聪梅于2026年3月5日至2026年3月9日间合计减持85.78万股，占公司目前总股本的0.0766%，变动期间该股股价上涨6.57%，截止3月9日收盘报45.75元。股东增减持详情见下表：根据海思科2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900027896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0033","BK0028","BK0239","BK0077","002653"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618414646","title":"海思科（002653）披露创新药HSK39297片上市许可申请获受理，3月9日股价下跌2.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618414646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618414646?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:16","pubTimestamp":1773047764,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘，海思科报收于45.75元，较前一交易日下跌2.8%，最新总市值为512.36亿元。该股当日开盘47.16元，最高48.47元，最低45.56元，成交额达1.43亿元，换手率为0.63%。海思科医药集团股份有限公司子公司四川海思科制药有限公司近日收到国家药品监督管理局下发的《受理通知书》，其自主研发的创新药HSK39297片的境内生产药品注册上市许可申请已获受理。目前该药还处于审评阶段，存在因审评不确定性导致审批进度变化的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900023274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK0077","BK0188","BK0033","BK0028","002653","BK0239","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618113692","title":"“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113692","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618113692?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:07","pubTimestamp":1773014820,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委：“十五五”期间将谋划1000个左右紧密型县域医共体建设3月7日，十四届全国人大 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2097828557.USD","LU2488822045.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU1997245094.SGD","LU2148510915.USD","LU2289578879.USD","BK0033","LU2580892789.USD","LU2495084118.USD","002653","LU1969619763.USD","BK0188","LU1997244956.HKD","LU1781817850.SGD","BK0183","LU0405327148.USD","LU1997245177.USD","BK0012","LU1328615791.USD","LU2097828631.EUR","BK0060","LU2328871848.SGD","LU1146622755.USD","LU1820825898.SGD","LU1580142542.USD","BK0077","LU2097828714.EUR","LU1255011170.USD","LU0405327494.USD","BK0196","LU1064131003.USD","BK0028","LU1655091616.SGD","600276","LU2097828474.EUR","688177","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617660115","title":"今晚，5家公司发布利好公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2617660115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617660115?lang=zh_cn&edition=full","pubTime":"2026-03-08 20:57","pubTimestamp":1772974620,"startTime":"0","endTime":"0","summary":"3月8日，多家上市公司发布利好公告。本次交易完成后，上市公司在电力能源领域的业务布局将得到拓展。该协议旨在提升中国企业的全球竞争力，为保障国家关键矿产资源战略安全、关键技术自主自立、促进高质量发展提供坚实支撑。同时，公司承诺调价透明审慎，涨幅匹配成本增加，不牟取超额利润，并提前告知预留规划时间。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-08/doc-inhqhuhc7434196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FBY","002340","FB","BK0070","BK0239","BK4553","BK4077","BK4533","BK0182","BK4573","BK0188","BK4581","BK4554","BK0083","METU","BK4503","BK0155","002653","BK0033","METD","BK4524","BK4579","BK0094","BK0077","BK0098","FBL","BK4550","BK0036","BK0200","BK4548","002445","BK0255","BK4527","BK0201","BK4534","BK4508","BK4551","METW","BK4525","BK4566","FBYY","BK4507","BK0028","BK0267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617661414","title":"海思科(002653.SZ)获得创新药HSK39297片上市许可《受理通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617661414?lang=zh_cn&edition=full","pubTime":"2026-03-08 15:48","pubTimestamp":1772956116,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司子公司四川海思科制药有限公司于近日收到国家药品监督管理局下发的HSK39297《受理通知书》，该药品适用于治疗阵发性睡眠性血红蛋白尿症(PNH)成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","06978","BK1574","BK1161","BK0033","BK0077","002653","BK0188","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776218943095,"stockEarnings":[{"period":"1week","weight":0.0477},{"period":"1month","weight":0.262},{"period":"3month","weight":0.0882},{"period":"6month","weight":0.1222},{"period":"1year","weight":0.2917},{"period":"ytd","weight":0.1395}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0241},{"period":"6month","weight":0.0282},{"period":"1year","weight":0.2341},{"period":"ytd","weight":0.0146}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海思科医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10654人(较上一季度增加0.84%)","perCapita":"50383股","listingDate":"2012-01-17","address":"西藏自治区山南市乃东区温雄大道43号","registeredCapital":"111991万元","survey":"　　海思科医药集团股份有限公司的主营业务是新药研发、生产制造、推广营销业务。公司的主要产品是环泊酚注射液、苯磺酸克利加巴林胶囊、考格列汀片、安瑞克芬注射液。海思科以“创新”为内核，获得了行业的高度认可，连续多年荣获“中国创新力医药企业”称号。在2022-2023年中国医药行业最具影响力榜单评选中，海思科荣膺四项殊荣，包括医药商业百强企业、医药制造业百强企业、自主创新先锋企业、守法诚信企业。2024年中国医药研发产品线荣获“最佳工业企业”奖项。2024年度中国医药工业主营业务收入第88位。2025年中国医药企业社会责任优秀案例，2025年中国创新药十年荣耀榜——行业引领制药企业。","listedPrice":20},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海思科,002653,海思科股票,海思科股票老虎,海思科股票老虎国际,海思科行情,海思科股票行情,海思科股价,海思科股市,海思科股票价格,海思科股票交易,海思科股票购买,海思科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海思科(002653)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海思科(002653)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}